# Open Orphan option to acquire CHIMagents Limited

- Link: https://www.directorstalkinterviews.com/open-orphan-option-to-acquire-chimagents-limited/412842796
- Published: 2020-07-15T07:12:42+01:00
- Author: Giles Arbor

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist CRO pharmaceutical services company which is the world
leader in the testing of vaccines and antivirals using human challenge clinical 
trials has announced that it has signed an option to acquire CHIMagents Limited 
for a nominal sum.

CHIMagents was recently established to assist in the design, manufacture and testing
of challenge agents for use in challenge studies. CHIMagents was established by 
an experienced team and have made great progress across a number of workstreams 
which will be highly valuable as part of the broader Open Orphan Group. CHIMagent’s
Adrian Wildfire has over 20 years of industry experience and will join hVIVO as 
Director, Scientific and Business Strategy.

Under the terms of the Option, Open Orphan will have three months to exercise its
option to acquire CHIMagents. Upon execution, CHIMagents will be a standalone company
within Open Orphan.

CHIMagents will support hVIVO with the design, manufacture and testing of both new
challenge agents and hVIVO’s industry leading portfolio of 8 existing challenge 
study agents. CHIMagents will also support hVIVO’s growing pipeline of challenge
study clinical trials and help in accelerating the development of hVIVO’s Covid-
19 challenge study clinical trials.

hVIVO’s pipeline of challenge studies is expected to grow further given the increasing
importance and focus on developing vaccines and anti-virals globally. Therefore,
the Option is an important strategic step for Open Orphan as it brings additional,
experienced resources to the Group and will ensure that Open Orphan can meet the
increased demand for its services as the world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.

> **Cathal Friel, Executive Chairman of Open Orphan, said:**
> “We look forward to working with Adrian Wildfire and the CHIMagents team going
> forward and this Option is an important strategic step for the business as we 
> rapidly grow our pipeline of challenge studies. The work CHIMagents is undertaking
> in relation to COVID-19 challenge agents also complements our own work and we 
> look forward to updating all shareholders on that workstream in due course. We
> have real momentum across the Group and this Option further cements our position
> as one of the leading service providers to the developers of vaccines and anti-
> virals globally.”

Share on:
